Biomarin Pharmaceutical Inc (BMRN)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 942,842 | 755,127 | 724,531 | 587,276 | 649,158 |
| Short-term investments | US$ in thousands | 194,864 | 318,683 | 567,006 | 426,599 | 416,228 |
| Receivables | US$ in thousands | 660,535 | 633,704 | 461,316 | 373,399 | 448,351 |
| Total current liabilities | US$ in thousands | 606,988 | 1,177,020 | 588,884 | 546,497 | 492,548 |
| Quick ratio | 2.96 | 1.45 | 2.98 | 2.54 | 3.07 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($942,842K
+ $194,864K
+ $660,535K)
÷ $606,988K
= 2.96
The quick ratio of Biomarin Pharmaceutical Inc has shown some fluctuations over the years, with the ratio standing at 3.07 as of December 31, 2020, indicating a strong ability to meet its short-term obligations with its most liquid assets. However, the ratio decreased to 2.54 by December 31, 2021, and then improved to 2.98 by December 31, 2022, still reflecting a relatively healthy liquidity position.
There was a significant decrease in the quick ratio to 1.45 by December 31, 2023, which may raise concerns about the company's short-term liquidity and ability to cover its immediate liabilities with its quick assets. However, the ratio recovered to 2.96 by December 31, 2024, showing an improvement in liquidity compared to the previous year.
Overall, while there have been fluctuations in Biomarin Pharmaceutical Inc's quick ratio over the years, it is important for the company to closely monitor its liquidity position to ensure it can effectively meet its short-term financial obligations.
Peer comparison
Dec 31, 2024